Managed Care Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
M.D. Anderson Cancer Center
Integrin-linked kinase inhibitor targets anaplastic thyroid cancer growth
October 9th, 2005
An integrin-linked kinase inhibitor targets anaplastic thyroid cancer growth. According to scientists in the United States, "we investigated integrin-linked kinase (ILK), a focal adhesion serine-threonine protein kinase, as a new molecular target for treating anaplastic thyroid cancer. ILK mediates cell growth and survival signals and is overexpressed in a number of cancers." "Therefore, we hypothesized that inhibition of ILK leads to growth arrest and apoptosis of thyroid cancer cells. According to Western blotting, the level of ILK protein was highly expressed in one papillary (NPA187) and four of five (Hth74, DRO, ARO, KAT4, and K4) anaplastic...
Source: Managed Care Law Weekly (2005-10-09)
|
